دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Kamlesh Khunti MD, PhD, Serge Jabbour MD, Xavier Cos MD, PhD, Sunder Mudaliar MD, Christian Mende MD, Marc Bonaca MD, Paola Fioretto MD, PhD
doi : 10.1111/dom.14684
Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including cardiovascular and renal protection.
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
Ralph A. DeFronzo MD, George L. Bakris MD
doi : 10.1111/dom.14696
In patients with type 2 diabetes, chronic kidney disease (CKD) is the most common cause of kidney failure. With its increasing prevalence and limited treatment options, CKD is a major contributor to the global burden of disease.
Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D): Study rationale, design, and methods
Donald C. Simonson MD, Bo Hu PhD, David E. Arterburn MD, Philip R. Schauer MD, Sangeeta R. Kashyap MD, Anita P. Courcoulas MD, David E. Cummings MD, Mary-Elizabeth Patti MD, William F. Gourash PhD, Ashley H. Vernon MD, John M. Jakicic PhD, John P. Kirwan PhD
doi : 10.1111/dom.14680
Long-term data from randomized clinical trials comparing metabolic (bariatric) surgery versus a medical/lifestyle intervention for treatment of patients with obesity/overweight and type 2 diabetes (T2D) are lacking.
Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community-based study
Brent A. Williams PhD, Jonathan P. Brady PharmD, Stephen Voyce MD, Neela Kumar MS, Yurek Paprocki MD, MBA, Jigar Rajpura PhD,Â
doi : 10.1111/dom.14686
To quantify changes over time in cardiovascular (CV) risk factor control and in the uptake of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors from 2007 to 2020 in a real-world community-based cohort of type 2 diabetes (T2D) patients.
Integrated metagenomics and metabolomics analysis illustrates the systemic impact of the gut microbiota on host metabolism after bariatric surgery
Yeyoung Han MSc, Gihyeon Kim MSc, Eunyong Ahn PhD, Sunhee Jung PhD, Youngae Jung PhD, Yunjae Kim BSc, Eunyoung Ha MD, PhD, Yoonseok Heo MD, PhD, Do Hyun Ryu PhD, Hansoo Park MD, PhD, Geum-Sook Hwang PhD,Â
doi : 10.1111/dom.14689
To explore how bariatric surgery (BS) modified the obesity-associated gut microbiome, the host metabolome, and their interactions in obese Korean patients.
Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin-treated type 2 diabetes: Results from a real-world nested case-control study
Julie Settles MSN, Hong Kan PhD, Christopher J. Child PhD, Magdaliz Gorritz MPH, Jasjit K. Multani MPH, Catherine B. McGuiness MS, Rolin L. Wade MS, Brian M. Frier MD,Â
doi : 10.1111/dom.14690
Several risk factors for severe hypoglycaemia (SH) are associated with insulin-treated diabetes. This study explored potential risk factors in adults with insulin-treated type 2 diabetes mellitus (T2DM).
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
Samuel Dagogo-Jack MD, DSc, Christopher P. Cannon MD, David Z. I. Cherney MD, PhD, Francesco Cosentino MD, PhD, Jie Liu MD, Annpey Pong PhD, Ira Gantz MD, Robert Frederich MD, James P. Mancuso PhD, Richard E. Pratley MD,Â
doi : 10.1111/dom.14691
To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose-lowering agent.
The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice
Qinghe Meng MD, Oleg G. Chepurny MD, PhD, Colin A. Leech PhD, Napat Pruekprasert BS, Megan E. Molnar BS, James Jason Collier PhD, Robert N. Cooney MD, George G. Holz PhD,Â
doi : 10.1111/dom.14693
To establish if alpha-7 nicotinic acetylcholine receptor (α7nAChR) agonist GTS-21 exerts a blood glucose-lowering action in db/db mice, and to test if this action requires coordinate α7nAChR and GLP-1 receptor (GLP-1R) stimulation by GTS-21 and endogenous GLP-1, respectively.
A low n-6 to n-3 polyunsaturated fatty acid ratio diet improves hyperinsulinaemia by restoring insulin clearance in obese youth
Domenico Tricò MD, Alfonso Galderisi MD, Michelle A. Van Name MD, Sonia Caprio MD, Stephanie Samuels MD, Zhongyao Li RD, Brittany T. Galuppo BS, Mary Savoye RD, Andrea Mari PhD, Ariel E. Feldstein MD, Nicola Santoro MD,Â
doi : 10.1111/dom.14695
To examine the determinants and metabolic impact of the reduction in fasting and postload insulin levels after a low n-6 to n-3 polyunsaturated fatty acid (PUFA) ratio diet in obese youth.
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
Anna Norhammar MD, Johan Bodegard MD, Jan W. Eriksson MD, Hermann Haller MD, Gerard C. M. Linssen MD, Amitava Banerjee MD, Avraham Karasik MD, Pavlos Mamouris PhD, Navdeep Tangri MD, Tiago Taveira-Gomes MD, Aldo P. Maggioni MD, Manuel Botana MD, Marcus Thuresson PhD, Suguru Okami PhD, Toshitaka Yajima MD, Takashi Kadowaki MD, KÃ¥re I. Birkeland MD, CaReMe Cardiorenal Investigators ,Â
doi : 10.1111/dom.14698
To examine how the development of cardiovascular and renal disease (CVRD) translates to hospital healthcare costs in individuals with type 2 diabetes (T2D) initially free from CVRD.
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
Subodh Verma MD, Mohammed Al-Omran MD, Lawrence A. Leiter MD, C. David Mazer MD, Søren Rasmussen PhD, Hans A. Saevereid MD, Maria Sejersten Ripa MD, Marc P. Bonaca MD,Â
doi : 10.1111/dom.14700
To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients with type 2 diabetes (T2D) and peripheral artery disease (PAD).
Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET)
Marc Evans MD, Abhishek Shankar Chandramouli BTech, Mads Faurby MSc, Kasper Sommer Matthiessen MSc, Phillip Bredahl Mogensen MSc, Subodh Verma MD,Â
doi : 10.1111/dom.14703
To investigate the budget implications of treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus other glucose-lowering treatment (here termed ‘standard of care’ [SoC]) during 2012-2019.
Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study
Martin B. Whyte PhD, Mark Joy PhD, William Hinton BSc, Andrew McGovern MD, Uy Hoang PhD, Jeremy van Vlymen BSc, Filipa Ferreira BSc, Julie Mount PhD, Neil Munro DPhil, Simon de Lusignan MD,Â
doi : 10.1111/dom.14705
To determine whether achieving early glycaemic control, and any subsequent glycaemic variability, was associated with any change in the risk of major adverse cardiovascular events (MACE).
In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial
Thekla von dem Berge MD, Kerstin Remus RN, Sarah Biester RN, Felix Reschke MD, Britta Klusmeier RN, Kerstin Adolph PhD, Anette Holtdirk MA, Andreas Thomas PhD, Olga Kordonouri MD, Thomas Danne MD, Torben Biester MD,Â
doi : 10.1111/dom.14706
To obtain additional information on the incremental differences between using a sensor-augmented pump (SAP) without automated insulin delivery (AID), using it with predictive low-glucose management (PLGM) or as hybrid closed loop (HCL), in preschool and school children.
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature review
Zi-Yang Peng MS, Chun-Ting Yang MS, Huang-Tz Ou PhD, Shihchen Kuo RPh, PhD,Â
doi : 10.1111/dom.14708
We conducted a model-based economic analysis of sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl peptidase-4 inhibitors (DPP4is) in patients with type 2 diabetes (T2D), with and without established cardiovascular diseases (CVDs), using 10-year real-world data.
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
Vanita R. Aroda MD, Robert Bauer PhD, Erik Christiansen DMSc, Martin HaluzÃk MD, Klaus Kallenbach PhD, Eduard Montanya MD, Julio Rosenstock MD, Juris J. Meier MD,Â
doi : 10.1111/dom.14710
To evaluate the efficacy and safety of oral semaglutide versus comparators by patient characteristic subgroups in patients with type 2 diabetes.
Types of diet, obesity, and incident type 2 diabetes: Findings from the UK Biobank prospective cohort study
Jirapitcha Boonpor MSc, Fanny Petermann-Rocha MSc, Solange Parra-Soto MSc, Jill P. Pell MD, Stuart R. Gray PhD, Carlos Celis-Morales PhD, Frederick K. Ho PhD,Â
doi : 10.1111/dom.14711
To investigate the associations between types of diet and incident type 2 diabetes and whether adiposity mediated these associations.
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Victoria E. R. Parker, Thuong Hoang, Heike Schlichthaar, Fraser W. Gibb, Barbara Wenzel, Maximillian G. Posch, Ludger Rose, Yi-Ting Chang, Marcella Petrone, Lars Hansen, Philip Ambery, Lutz Jermutus, Hiddo J. L. Heerspink, Rory J. McCrimmon,Â
doi : 10.1111/dom.14712
To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease.
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users
Arcelia Arrieta MSc, Tadej Battelino MD, Andrea E. Scaramuzza MD, Julien Da Silva MSc, Javier Castañeda MSc, Toni L. Cordero PhD, John Shin PhD, Ohad Cohen MD,Â
doi : 10.1111/dom.14714
To investigate real-world glycaemic outcomes and goals achieved by users of the MiniMed 780G advanced hybrid closed loop (AHCL) system aged younger and older than 15 years with type 1 diabetes (T1D).
Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
Megan O. Bensignor M.D., Jack M. Wolf B.A., Kyle D. Rudser Ph.D, Aaron S. Kelly Ph.D., Silva Arslanian M.D.,Â
doi : 10.1111/dom.14681
The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes
Pei Chia Eng, Walter Distaso, Hashmi Durreshahwar, Yusuf Shaikhali, Divani Narendranathan, Rebecca Cassin-Scott, Shivani Misra, Neil E. Hill, George Tharakan, Nick S. Oliver, Tricia M. Tan, Chioma Izzi-Engbeaya, Victoria Salem,Â
doi : 10.1111/dom.14692
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals
Rajiv Agarwal MD, MS, Sibylle Jenny Hauske MD, David C. Wheeler MD, Kent Doi PhD, Amelie Elsaesser PhD, Ivana Ritter MD, Dominik Steubl MD, Christoph Wanner MD,Â
doi : 10.1111/dom.14694
Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes
Thomas R. Pieber MD, Ronnie Aronson MD, Mark P. Christiansen MD, Bruce Bode MD, Khaled Junaidi MD, Valentina Conoscenti MD,Â
doi : 10.1111/dom.14699
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists
Thomas S. J. Crabtree, Karen Adamson, Hazel Reid, Dennis Barnes, Siva Sivappriyan, Alex Bickerton, Ian W. Gallen, Benjamin C. T. Field, Iskandar Idris, Robert E. J. Ryder, on behalf of all ABCD semaglutide audit contributors ,Â
doi : 10.1111/dom.14701
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure.
Association between antidiabetic drug use and the risk of COVID-19 hospitalization in the INSIGHT Clinical Research Network in New York City
JeaYoung Min PharmD, Will Simmons MPH, Samprit Banerjee PhD, Fei Wang PhD, Nicholas Williams MPH, Yongkang Zhang PhD, April B. Reese MPH, Alvin I. Mushlin MD, James H. Flory MD,Â
doi : 10.1111/dom.14704
